INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

Zacks
Ouvrir sur Zacks
INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

Inspire Medical Systems, Inc. INSP shares have gained 12.1% in the past three months, even as reimbursement disruption has continued to weigh on procedure conversion and revenues.

The next leg of the rally depends on whether improving operating trends and a clearer path to 2027 growth can offset still-soft near-term fundamentals.

INSP's Three-Month Gain Meets a Mixed Fundamental Backdrop

Third-quarter 2026 revenues fell 7.9% year over year to $206.7 million, while adjusted earnings per share (EPS) dropped 62.2% to 14 cents. Both metrics still topped the Zacks Consensus Estimate, with revenues beating by 1.2% and earnings exceeding the consensus mark by 40%.

The quarter also showed sequential progress. Revenues rose 3% from the second quarter as U.S. implanting centers became more comfortable with the temporary coding framework, helping explain why the stock's recent momentum has strengthened despite year-over-year contraction.

Inspire Medical Systems, Inc. Price and Consensus

Inspire Medical Systems, Inc. Price and Consensus

Inspire Medical Systems, Inc. price-consensus-chart | Inspire Medical Systems, Inc. Quote

Reimbursement Friction Still Caps Inspire's Conversion

Coding and reimbursement issues reduced third-quarter revenues by approximately $30 million and Inspire Medical expects the full-year 2026 impact to reach roughly $120 million. Surgeon reimbursement remains inconsistent, while the WISeR prior-authorization program in six Medicare pilot states continues to add administrative steps that can delay procedures.

The broader treatment landscape also keeps patient conversion competitive. ResMed Inc. RMD remains a major provider of continuous positive airway pressure therapy, the frontline standard of care for obstructive sleep apnea. Nyxoah SA NYXH, meanwhile, focuses on obstructive sleep apnea through its Genio system, a bilateral hypoglossal nerve stimulation therapy.

INSP's 2027 Recovery Case Depends on Patient Flow

Management expects low-single-digit worldwide revenue growth in 2027, supported by a more stable coding environment, growth investments and a larger contribution from battery replacement procedures. That outlook suggests recovery, but not a rapid return to the company's earlier growth profile.

Project Horizon is central to the plan. The program created approximately $30 million of annualized investment capacity, which Inspire is redirecting toward patient engagement, education, navigation and additional field resources in about 40 high-potential markets.

Inspire's Valuation Leaves Room but Not a Clear Bargain

INSP trades at 2.1X forward 12-month sales, below its five-year median of 6.5X and the Zacks sub-industry's 4.3X. The discount leaves room for multiple expansion if revenue growth stabilizes and reimbursement execution improves.

Still, valuation alone does not settle the case. The Zacks Consensus Estimate calls for 2026 revenues of $856 million, down from $912 million in 2025, while adjusted earnings are projected at $1.29 per share versus $2.42 in 2025.

Zacks Investment Research
Image Source: Zacks Investment Research

INSP's Momentum Signal Offsets Softer Growth Scores

The rally can continue if procedure conversion improves and the 2027 growth plan gains traction, but reimbursement execution remains the key swing factor. The current setup supports a balanced view rather than an aggressive chase after the recent gain.

Year to date, shares of Inspire Medical declined 30.3% against the industry’s 23.1% growth. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Zacks Investment Research
Image Source: Zacks Investment Research

INSP currently carries a Zacks Rank #3 (Hold) and a VGM Score of B. Its Momentum Score of A fits the recent share-price strength and a 3.4% four-week increase in the current-year earnings estimate, while the Value Score of C and Growth Score of C temper that signal. The combination suggests improving momentum, but not enough evidence yet for a clearly stronger investment stance.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Inspire Medical Systems, Inc. (INSP): Free Stock Analysis Report
 
ResMed Inc. (RMD): Free Stock Analysis Report
 
Nyxoah SA (NYXH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research